Please use this identifier to cite or link to this item: http://inet.vidyasagar.ac.in:8080/jspui/handle/123456789/5918
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorRoy, Somenathen_US
dc.contributor.advisorSaha, Bhaskaren_US
dc.contributor.authorKumar, Sunil-
dc.date.accessioned2021-03-16T10:54:11Z-
dc.date.available2021-03-16T10:54:11Z-
dc.date.issued2021-02-25-
dc.identifier.otherThesis;-
dc.identifier.urihttp://inet.vidyasagar.ac.in:8080/jspui/handle/123456789/5918-
dc.description.abstractJenner and Pasteur used to take an old culture or crude source of pathogen and introduce into vaccine even though not knowing the causative agent of the pathogen. This practice called variolation led to revolution because the person became resistant to the same pathogen or other pathogens that related to this original pathogen. The protection was associated with the poxvirus even though not knowing the mechanism related to protection. Later on, Leishmania, a protozoan parasite, was discovered, its structure was revealed and the genome was sequenced. Leishmaniasis is considered as neglected vector-borne diseases of the impoverished. The causative agent belongs to eukaryotic species of dimorphic, obligate, protozoan parasites of the genus Leishmania. Leishmania belongs to the order kinetoplastida and the family trypanosomatidae. Inside the host, these Leishmania parasites have a cellular niche known as macrophages wherein they survive and replicate. Being the primary host cells for the Leishmania parasite and an important cell type in the innate immune system, macrophages are responsible for killing the Leishmania parasite. Thus, the nature of interactions between the host and the parasite solely decides the outcome of Leishmania infection. However, the chemotherapeutic elimination of the parasite is challenged by the requirement of prolonged treatments or exorbitantly priced Ambisome, or highly toxic drugs such as miltefosine and resistance to the drug in prolonged use such as antimony. Therefore, an alternative is prophylactic immunization using a vaccine. Unfortunately, despite long trials, an effective anti-leishmanial vaccine remains elusive. MAPK10 (Mitogen-activated protein kinase10) a cytosolic signaling intermediate protein, having homology with mammalian host ERK-2 is therefore given a pre-clinical trial in a mouse model. As L. major derived MAPK10 gene shows host-protective effect in BALB/c mice, a susceptible host against experimental cutaneous leishmaniasis, we sought to determine whether priming with the same gene, i.e., MAPK10 would offer cross-protective efficacy against L. donovani infection. We observed that priming with MAPK10 DNA in a mammalian expression vector significantly reduced the parasite burden, especially, in spleen and liver, associated with elevated NO production. The protection was associated with host-protective T-cell functions, TH1-derived cytokines, and enhanced leishmanial antigen-specific IgG2a isotype response. The T-cell response against L. donovani infection was linked with an increase in IL-12 and IFN-γ, but reduced IL-10 and IL-4 production. These findings clearly support the cross- protective efficacy of LmjMAPK10 vaccination against L. donovani infection and the role of T-cells in the protection. A cytokine that regulates T-cell growth is IL-7. IL-7 is a non- hematopoietic stromal cell, not a T-cell, B-cell or NK cell-derived cytokine, secreted cytokine in thymic and bone marrow environment and is responsible for T-cell development and homeostasis. IL-7 works through its receptor that is comprised of two subunits- IL-7Rα (CD127) common wit h thymic stromal lymphopoietin (TSLP) and common γ chain (CD132). Binding of IL-7 with its receptor initiates signaling through JAK-STAT and PI3K/AKT pathway associated with survival and differentiation. As we previously reported that MAPK10 or M10 offers cross-protection against L. donovani infection. So, we sought to determine whether priming BALB/c mice (a susceptible model) with M10+rmIL-7 (recombinant murine IL-7) does regulate directly anti-leishmanial function. We found that immunized L. donovani infected mice significantly reduce the parasite burden in visceral organ spleen and liver as well as in Macrophage T-Cell co-culture in vitro. In addition, we noticed that CSA-stimulated splenocyte culture supernatant induced IL-12 and IFN-γ followed by a reduction in IL-10 and IL-4 production. As IL-12 promotes IFN-γ production that switches IgM to IgG2a and IL-10 facilitates IgG1 production, we collected sera from Immunized mice before and after infection.We found heightened IgG2a but suppressed IgG1 and IgM. The protection is also related to host protective T-cell function, TH and humoral response. However, an increase in TH1 type cellular 1 cytokine IL-12 and suppressed TH2, i.e., IL-4 and IL-10 production from macrophage T-cell co-culture supernatant accompanied by NO-mediated controlled parasite replication. These corroborative results suggest that M10+IL-7 regulated anti-leishmanial function against L. donovani infection in BALB/c susceptible mouse model.en_US
dc.language.isoenen_US
dc.publisherVidyasagar University, Midnapore, West Bengal, India,en_US
dc.subjectLeishmania infectionen_US
dc.subjectMemory T-cell generationen_US
dc.subjectMemory T-Cell Generation - Characterizationen_US
dc.titleCharacterization of priming induced memory T-cell generation in Leishmania infectionen_US
dc.typeThesisen_US
Appears in Collections:Human Physiology with Community Health - Ph.D

Files in This Item:
File Description SizeFormat 
01_title.pdf131.58 kBAdobe PDFView/Open
02_certificate_a.pdf811.26 kBAdobe PDFView/Open
02_certificate_b.pdf807.49 kBAdobe PDFView/Open
03_abstract.pdf408.45 kBAdobe PDFView/Open
04_declaration.pdf631.25 kBAdobe PDFView/Open
05_acknowledgement.pdf44.81 kBAdobe PDFView/Open
06_contents.pdf22.78 kBAdobe PDFView/Open
07_list_of_tables.pdf4.57 kBAdobe PDFView/Open
08_list_ of_ figures.pdf21.5 kBAdobe PDFView/Open
09_abbreviations.pdf349.41 kBAdobe PDFView/Open
10_chapter1.pdf1.81 MBAdobe PDFView/Open
11_chapter2.pdf292.2 kBAdobe PDFView/Open
12_chapter3.pdf292.96 kBAdobe PDFView/Open
13_chapter4.pdf1.36 MBAdobe PDFView/Open
14_chapter5.pdf426.6 kBAdobe PDFView/Open
15_summary.pdf411.19 kBAdobe PDFView/Open
16_conclusion.pdf388.77 kBAdobe PDFView/Open
17_conferences.pdf291.55 kBAdobe PDFView/Open
18_bibliography.pdf485.6 kBAdobe PDFView/Open
19_publications.pdf293.99 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.